Oncology Development Articles & Analysis
56 news found
Carcinotech and CELLINK are pleased to announce a collaborative partnership to develop and commercialize protocols for the biofabrication of 3D bioprinted tumor models based on cancer cell lines that improve accuracy and rapidly speed up drug development processes, driving down development costs and enabling an improved output. ...
ByCELLINK
“Many patients with rising PSA levels following surgery or radiation are at an increased risk of developing metastasis. With ARASTEP, we are optimistic about the potential to help patients at this earlier stage of the disease,” said Tara Frenkl, M.D., Senior Vice President and Head of Oncology Development at Bayer. ...
ByBayer AG
“Our business model is driven by an understanding that scalable infrastructures, like those we have and are developing, are an indispensable prerequisite to foster clinical accessibility, affordability, and market penetration of precision medicine tools,” said Dr. ...
This latest subgroup analysis from the ARASENS trial highlights darolutamide’s potential to become a foundational therapy for patients with various types of metastatic disease burden,” said Tara Frenkl, M.D., Senior Vice President and Head of Oncology Development at Bayer. “An important part of our mission at Bayer is to transform prostate ...
ByBayer AG
She added, “As medicine moves towards personalized care, more precise cell recovery is required for research and pharmaceutical development, especially in the new fields of cell therapeutics and genomics. ...
(“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing novel treatments for breast and gynecologic cancers, announced preliminary Phase 2 data from the ongoing SMILE trial of onapristone extended release (ONA-XR), the company’s novel, first-in-class, potent, orally administered progesterone receptor ...
Novartis has strong medicinal chemistry, oncology development and translational research capabilities to realize the full potential of this novel cancer target,” said Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys. “At MorphoSys, we will continue to focus our resources on driving our late- and mid-stage oncology pipeline ...
BC Platforms (BCP), a global leader in healthcare data management and analytics, today announced that, together with Finland’s Euformatics and Hungary’s Oncompass Medicine, the BCP-led partnership has now successfully been awarded contract for the second phase of developing standardized oncology workflows for a buyer consortium of seven leading ...
She brings with her extensive knowledge and experience in the field of Immuno-Oncology and drug discovery, which is strategic for Ardigen’s development. Agnieszka Blum, MD, PhD will continue her mission as the General Director of the Immunology Business Unit at Ardigen, where she focuses on developing AI platforms to solve therapy ...
ByArdigen
About BriaCell Therapeutics Corp. BriaCell is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for the management of ...
Details on the poster presentations are as follows: Poster ID: P1-05-28 Date: Tuesday, December 6, 2022 Time: 5:00 PM - 6:15 PM Poster ID: P3-07-12 Poster ID: P3-06-08 Date: Wednesday, December 7, 2022 Time: 5:00 PM - 6:15 PM About BriaCell Therapeutics Corp. BriaCell is an immuno-oncology-focused biotechnology company developing targeted and effective ...
Under the terms of the agreement, BriaCell gains the worldwide rights to develop and commercialize sCD80, while UMBC maintains ownership of the patents. ...
(Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced an appointment to its executive team to lead the Company’s business development efforts. ...
Extended survival and tumor shrinkage in advanced breast cancer patients who matched the immunotherapy HLA types, lead to the development of BriaCell’s prostate cancer program based on the patient’s HLA type. ...
Establishment of new precision molecular oncology research center to drive development of novel targeted cancer therapies for patients with unmet medical need Strategic investment of $140M USD to expand presence in leading center of biotech innovation at Kendall Square in Cambridge Fostering close collaboration with scientists, enhancing global network of ...
ByBayer AG
Included in her reporting responsibilities were clinical development, clinical operations, clinical pharmacology, biometrics, translational research, program management and medical affairs. ...
ByBayer AG
No treatment-related deaths occurred. “Taiho Oncology remains committed to addressing unmet treatment needs in patients living with a broad range of cancers, and these data from the FOENIX-CCA2 trial demonstrate the clinical activity of futibatinib,” said Volker Wacheck, Vice President, Clinical Development, Taiho Oncology, Inc. ...
” As Chief Medical and Development Officer, Dr. Rajangam will be broadly responsible for leading the development and regulatory strategy to rapidly advance Senti Bio's off-the-shelf CAR-NK cell oncology programs into and through clinical development. ...
Alessandro Riva, Transgene’s Chairman, added: “I’m delighted to be joining Transgene, an increasingly important player in the oncology space as the Company prepares for the next key steps in its evolution. ...
.; in the U.S., Taiho and Cullinan Oncology to jointly develop and co-commercialize CLN-081/TAS6417 Cullinan Oncology will receive an upfront cash payment of $275 million, with potential to receive up to an additional $130 million in regulatory-based milestone payments Cullinan Oncology and Taiho will equally share future ...